NASDAQ:ACAD ACADIA Pharmaceuticals (ACAD) Stock Price, News & Analysis $14.73 -0.10 (-0.67%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$14.74 +0.01 (+0.07%) As of 04/25/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ACADIA Pharmaceuticals Stock (NASDAQ:ACAD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ACADIA Pharmaceuticals alerts:Sign Up Key Stats Today's Range$14.47▼$14.8350-Day Range$14.10▼$20.3752-Week Range$13.40▼$20.68Volume957,583 shsAverage Volume1.85 million shsMarket Capitalization$2.46 billionP/E Ratio18.88Dividend YieldN/APrice Target$23.93Consensus RatingModerate Buy Company OverviewACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Read More… ACADIA Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreACAD MarketRank™: ACADIA Pharmaceuticals scored higher than 86% of companies evaluated by MarketBeat, and ranked 187th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 8 buy ratings, 8 hold ratings, and no sell ratings.Amount of Analyst CoverageACADIA Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ACADIA Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth8.57% Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow by 8.57% in the coming year, from $0.70 to $0.76 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is 18.88, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 21.68.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is 18.88, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 22.39.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 5.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ACADIA Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.84% of the float of ACADIA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 1.92%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted12.84% of the float of ACADIA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 1.92%, indicating that investor sentiment is improving. News and Social Media3.0 / 5News Sentiment1.34 News SentimentACADIA Pharmaceuticals has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for ACADIA Pharmaceuticals this week, compared to 8 articles on an average week.Search InterestOnly 3 people have searched for ACAD on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $242,686.00 in company stock.Percentage Held by Insiders28.30% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.71% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ACADIA Pharmaceuticals' insider trading history. Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Stock News HeadlinesJames Kihara Sells 1,095 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) StockMarch 27, 2025 | insidertrades.comRyan Reynolds Reflects on Father's Battle with Parkinson's Disease and the Importance of Modern TreatmentsApril 26 at 10:01 AM | msn.comThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.April 26, 2025 | Paradigm Press (Ad)“That’s not easy” - A Decade After His Father’s Death, Ryan Reynolds Opens Up About His Struggles With Parkinson’s DiseaseApril 26 at 4:58 AM | msn.comRyan Reynolds Reacts to Blake Lively's Speech Where She Alluded to Justin Baldoni Legal Battle (Exclusive)April 26 at 4:58 AM | msn.comRyan Reynolds Shares the Sweet Family Tradition His Father Started That He's Continuing with His 4 Kids (Exclusive)April 26 at 4:58 AM | msn.comAcadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025April 23 at 4:05 PM | businesswire.comAcadia Pharmaceuticals price target lowered to $18 from $19 at BofAApril 20, 2025 | markets.businessinsider.comSee More Headlines ACAD Stock Analysis - Frequently Asked Questions How have ACAD shares performed this year? ACADIA Pharmaceuticals' stock was trading at $18.35 at the beginning of 2025. Since then, ACAD stock has decreased by 19.7% and is now trading at $14.73. View the best growth stocks for 2025 here. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.14 by $0.06. The company's revenue for the quarter was up 18.3% compared to the same quarter last year. Read the conference call transcript. Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' top institutional shareholders include Assenagon Asset Management S.A. (2.20%), Rhumbline Advisers (0.21%), Allspring Global Investments Holdings LLC (0.19%) and Hennion & Walsh Asset Management Inc. (0.08%). Insiders that own company stock include Bros Advisors Lp Baker, Stephen Davis, Brendan Teehan, Srdjan R Stankovic, Mark C Schneyer, Austin D Kim, James Kihara, Elizabeth A Garofalo and Laura Brege. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ACADIA Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings11/06/2024Today4/26/2025Next Earnings (Estimated)5/07/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACAD CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees510Year FoundedN/APrice Target and Rating Average Stock Price Target$23.93 High Stock Price Target$31.00 Low Stock Price Target$19.00 Potential Upside/Downside+62.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)$1.36 Trailing P/E Ratio18.88 Forward P/E Ratio21.04 P/E GrowthN/ANet Income$-61,290,000.00 Net Margins13.83% Pretax Margin14.71% Return on Equity25.83% Return on Assets14.71% Debt Debt-to-Equity RatioN/A Current Ratio2.29 Quick Ratio2.11 Sales & Book Value Annual Sales$957.80 million Price / Sales2.57 Cash FlowN/A Price / Cash FlowN/A Book Value$2.63 per share Price / Book5.60Miscellaneous Outstanding Shares166,789,000Free Float119,303,000Market Cap$2.46 billion OptionableOptionable Beta0.54 Social Links Free Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ACAD) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDeepSeek’s Clear and Present DangerDeepSeek — the alleged “$5.5 million” AI project — isn’t an open-source breakthrough. It’s a Trojan horse.Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.